Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    veinplicity | viva
Previous Study | Return to List | Next Study

Veinplicity for Improved Venous Access: The VIVA Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03752632
Recruitment Status : Terminated (Business reasons not related to safety or trial conduct)
First Posted : November 26, 2018
Last Update Posted : October 30, 2019
Sponsor:
Collaborator:
Regulatory Clinical Research Institute (RCRI)
Information provided by (Responsible Party):
Physeon GmbH

Brief Summary:
This study will assess the safety and effectiveness of the Veinplicity device to improve the visualization and palpability of difficult-to-access veins for intravenous cannulation.

Condition or disease Intervention/treatment Phase
Difficult-to-access Veins for Intravenous Cannulation Device: Veinplicity with tourniquet Device: Tourniquet Phase 3

Detailed Description:
This is a prospective, randomized controlled study that will assess ability of Veinplicity to improve successful peripheral vein cannulation at the first stick in enrolled subjects. Potential subjects will undergo a peripheral vein assessment by a study clinician, which is standard of care prior to peripheral vein cannulation (PVC) for the establishment of intravenous (IV) access. Adults who are assessed as having "fair or poor" vein quality will be consented, enrolled and randomized into the study. Subjects will be randomized in a 1:1 ratio to either (1) tourniquet alone (control group); or (2) Veinplicity with tourniquet (treatment group). The primary endpoint is first-stick success. Clinicians will use an 18-, 20- or 22-gauge cannula. Clinician and subject satisfaction will be separately assessed using surveys on Day 0. Subjects in both groups will be followed for one day (either phone or in-hospital visit) after enrollment for safety. Qualified study clinicians must have at least one year of experience inserting peripheral IVs and must perform an average of five PVCs per week. The primary hypothesis to be tested is: Veinplicity with tourniquet is superior to tourniquet alone for successful peripheral vein access at first stick when used to cannulate subjects assessed as having a fair or poor level of vein quality. It is expected that this study will enroll approximately 246 subjects; 123 per study group. It is expected that up to five sites will be involved in this study. A planned interim analysis will be conducted to reassess the study planned sample size when approximately 50% of subjects have been enrolled. Enrollment will not stop during the interim analysis activities. Safety will be evaluated by the collection and analysis of the incidence and severity of all procedure- and/or device-related adverse events through the Day 1 phone call/visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Veinplicity for Improved Venous Access: The VIVA Trial
Actual Study Start Date : November 1, 2018
Actual Primary Completion Date : July 22, 2019
Actual Study Completion Date : July 22, 2019

Arm Intervention/treatment
Experimental: Veinplicity with tourniquet (treatment)
Veinplicity with tourniquet
Device: Veinplicity with tourniquet
Veinplicity will be used with a tourniquet

Active Comparator: Tourniquet (control)
Control: Tourniquet
Device: Tourniquet
A tourniquet alone will be used.




Primary Outcome Measures :
  1. First-stick success when accessing a peripheral vein for cannulation [ Time Frame: Day 0 ]
    successful peripheral vein access for the first-stick with use of Veinplicity with tourniquet versus tourniquet alone

  2. Device and/or procedure-related adverse events [ Time Frame: Day 1 ]
    Safety will be evaluated by the collection and analysis of the incidence and severity of all procedure- and/or device-related adverse events through the Day 1 post-insertion phone call/visit.


Other Outcome Measures:
  1. Number of attempted sticks to successful vein access [ Time Frame: Day 0 ]
    Number of attempted sticks to successful vein access

  2. Total procedure time [ Time Frame: Day 0 ]
    For control subjects, timing begins at the start of skin preparation or tourniquet application on the first arm (whichever is first per standard of practice) to either obtaining successful vein access or until the fourth attempt at cannulation fails. For Veinplicity subjects, timing begins at the start of electrode application on the first arm to either obtaining successful vein access or until the fourth attempt at cannulation fails.

  3. Time to first-stick success [ Time Frame: Day 0 ]
    time from tourniquet application for the initial cannulation attempt to declaration of first-stick success/failure.

  4. Subject Satisfaction Survey question for control subject's: Past IV starts have been difficult, uncomfortable or painful. [ Time Frame: Day 0 after completion of the study procedure ]

    Control subject's assessment of pain associated with past IV starts:

    Scale 1 - 5; Unable to Evaluate

    1. Strongly Agree
    2. Agree
    3. Neutral
    4. Disagree
    5. Strongly Disagree Unable to Evaluate

  5. Subject Satisfaction Survey question for control subject's: Today, my IV was started easily. [ Time Frame: Day 0 after completion of the study procedure ]

    Control subject's assessment of how easy they believe today's IV start was:

    Scale 1 - 5; Unable to Evaluate

    1. Strongly Agree
    2. Agree
    3. Neutral
    4. Disagree
    5. Strongly Disagree Unable to Evaluate

  6. Subject Satisfaction Survey question for control subject's: Pain associated with IV start procedure today. [ Time Frame: Day 0 after completion of the study procedure ]

    Control subject's assessment of pain level associated with today's IV start procedure:

    Scale 1 - 5; Unable to Evaluate

    1. Not painful at all
    2. Almost no pain
    3. Some pain
    4. Moderate pain
    5. Extreme pain Unable to Evaluate

  7. Subject Satisfaction Survey question for control subject's: Pain associated with today's IV start compared to past IV starts. [ Time Frame: Day 0 after completion of the study procedure ]

    Control subject's assessment of pain associated with today's IV start compared to past IV starts:

    Scale 1 - 5; Unable to Evaluate

    1. Much less pain
    2. Less Painful
    3. Equal Pain
    4. More Painful
    5. Much More Painful Unable to Evaluate

  8. Subject Satisfaction Survey question for control subject's: Anxiety associated with the IV start procedure today. [ Time Frame: Day 0 after completion of the study procedure ]

    Control subject's assessment of anxiety level associated with today's IV start procedure:

    Scale 1 - 5; Unable to Evaluate

    1. Not Anxious
    2. Slightly Anxious
    3. Anxious
    4. Moderately Anxious
    5. Very Anxious Unable to Evaluate

  9. Subject Satisfaction Survey question for control subject's: Anxiety associated with today's IV start compared to past IV starts. [ Time Frame: Day 0 after completion of the study procedure ]

    Control subject's assessment of anxiety level associated with today's IV start procedure compared to past IV starts:

    Scale 1 - 5; Unable to Evaluate

    1. A Lot Less Anxious
    2. Less Anxious
    3. The Same
    4. More Anxious
    5. Very Anxious Unable to Evaluate

  10. Subject Satisfaction Survey question for control subject's: Overall, I was satisfied with today's IV start. [ Time Frame: Day 0 after completion of the study procedure ]

    Control subject's overall assessment of satisfaction with today's IV start:

    Scale 1 - 5; Unable to Evaluate

    1. Strongly Agree
    2. Agree
    3. Neutral
    4. Disagree
    5. Strongly Disagree Unable to Evaluate

  11. Subject Satisfaction Survey question for treatment subject's: Past IV starts have been difficult, uncomfortable or painful. [ Time Frame: Day 0 after completion of the study procedure ]

    Veinplicity subject's assessment of pain associated with past IV starts:

    Scale 1 - 5; Unable to Evaluate

    1. Strongly Agree
    2. Agree
    3. Neutral
    4. Disagree
    5. Strongly Disagree Unable to Evaluate

  12. Subject Satisfaction Survey question for treatment subject's: Today, my IV was started easily. [ Time Frame: Day 0 after completion of the study procedure ]

    Veinplicity subject's assessment of how easy they believe today's IV start was:

    Scale 1 - 5; Unable to Evaluate

    1. Strongly Agree
    2. Agree
    3. Neutral
    4. Disagree
    5. Strongly Disagree Unable to Evaluate

  13. Subject Satisfaction Survey question for treatment subject's: Pain associated with IV start procedure today. [ Time Frame: Day 0 after completion of the study procedure ]

    Veinplicity subject's assessment of pain level associated with today's IV start procedure:

    Scale 1 - 5; Unable to Evaluate

    1. Not painful at all
    2. Almost no pain
    3. Some pain
    4. Moderate pain
    5. Extreme pain Unable to Evaluate

  14. Subject Satisfaction Survey question for treatment subject's: Pain associated with today's IV start compared to past IV starts. [ Time Frame: Day 0 after completion of the study procedure ]

    Veinplicity subject's assessment of pain level associated with today's IV start compared to past IV starts:

    Scale 1 - 5; Unable to Evaluate

    1. Not painful at all
    2. Almost no pain
    3. Some pain
    4. Moderate pain
    5. Extreme pain Unable to Evaluate

  15. Subject Satisfaction Survey question for treatment subject's: Anxiety associated with the IV start procedure today. [ Time Frame: Day 0 after completion of the study procedure ]

    Veinplicity subject's assessment of anxiety level associated with today's IV start procedure:

    Scale 1 - 5; Unable to Evaluate

    1. Not Anxious
    2. Slightly Anxious
    3. Anxious
    4. Moderately Anxious
    5. Very Anxious Unable to Evaluate

  16. Subject Satisfaction Survey question for treatment subject's: Anxiety associated with today's IV start compared to past IV starts. [ Time Frame: Day 0 after completion of the study procedure ]

    Veinplicity subject's assessment of anxiety level associated with today's IV start procedure compared to past IV starts:

    Scale 1 - 5; Unable to Evaluate

    1. A Lot Less Anxious
    2. Less Anxious
    3. The Same
    4. More Anxious
    5. Very Anxious Unable to Evaluate

  17. Subject Satisfaction Survey question for treatment subject's: Pain associated with the Veinplicity stimulation. [ Time Frame: Day 0 after completion of the study procedure ]

    Veinplicity subject's assessment on level of pain associated with today's Veinplicity stimulation:

    Scale 1 - 5; Unable to Evaluate

    1. Not painful at all
    2. Almost no pain
    3. Some pain
    4. Moderate pain
    5. Extreme pain Unable to Evaluate

  18. Subject Satisfaction Survey question for treatment subject's: Veinplicity improved the overall success of my experience. [ Time Frame: Day 0 after completion of the study procedure ]

    Veinplicity subject's assessment on how Veinplicity improved overall success of their experience today:

    1. Strongly Agree
    2. Agree
    3. Neutral
    4. Disagree
    5. Strongly Disagree Unable to Evaluate

  19. Subject Satisfaction Survey question for treatment subject's: The Veinplicity device made it easier for the nurse to find a vein for my IV start today. [ Time Frame: Day 0 after completion of the study procedure ]

    Veinplicity subject's assessment of Veinplicity device made it easier for nurse to find a vein for today's IV start:

    1. Strongly Agree
    2. Agree
    3. Neutral
    4. Disagree
    5. Strongly Disagree Unable to Evaluate

  20. Subject Satisfaction Survey question for treatment subject's: I would choose the Veinplicity again for future IV starts. [ Time Frame: Day 0 after completion of the study procedure ]

    Veinplicity subject's likelihood of choosing to use the Veinplicity device for future IV starts:

    1. Definitely Agree
    2. Agree
    3. Neutral
    4. Disagree
    5. Definitely Disagree Unable to Evaluate

  21. Subject Satisfaction Survey question for treatment subject's: Overall, I was satisfied with today's IV start. [ Time Frame: Day 0 after completion of the study procedure ]

    Veinplicity subject's overall assessment of satisfaction with today's IV start:

    Scale 1 - 5; Unable to Evaluate

    1. Strongly Agree
    2. Agree
    3. Neutral
    4. Disagree
    5. Strongly Disagree Unable to Evaluate

  22. Clinician satisfaction [ Time Frame: Assessed on Day 0 after completion of the study procedure ]

    On Day 0 after each Veinplicity subject's IV procedure, each clinician will complete a Clinician Satisfaction Survey, after cannulation has been attempted and subject is declared either a study success or failure. Clinician's are not to complete this survey for control subjects.

    Scale 1 to 5:

    1. = Strongly Agree
    2. = Moderately Agree
    3. = Neutral
    4. = Moderately Disagree
    5. = Strongly Disagree QUESTION 1: Veinplicity was easy to use. QUESTION 2: Veinplicity improved vein palpability. QUESTION 3: Veinplicity improved vein visualization. QUESTION 4: Veinplicity made it easier to identify a suitable vessel to access.

    QUESTION 5: Veinplicity improved the overall success of the experience. QUESTION 6: Veinplicity resulted in a more positive and less anxious experience for the patient.

    QUESTION 7: I would recommend Veinplicity to a colleague or patient. QUESTION 8: Overall, I was satisfied with using the Veinplicity device.


  23. Change in the vein quality score from baseline to pre-cannulation tourniquet application [ Time Frame: Day 0 ]

    scores at baseline and post-stimulation to be assessed at time of tourniquet application by the same clinician.

    Scale = Vessel Health and Preservation (VHP) Peripheral Vein Assessment Scale. Grade 1 = Vein Quality Excellent (4-5 palpable/easily visible veins suitable to cannulate) Grade 2 = Vein Quality Good (2-3 palpable/visible veins suitable to cannulate Grade 3 = Vein Quality Fair (1-2 palpable/visible veins suitable to cannulate [veins may be small, scarred or difficult to find and require heat packs to aid vasodilation]) Grade 4 = Vein Quality Poor (veins not palpable/visible [requires ultrasound assistance or infrared viewer]) Grade 5 = Vein Quality None identifiable (no visible [naked eye or aids] or palpable veins) Fair or Poor indicates to clinician that cannulation may be challenging and require extra time or resources; use of Veinplicity may increase vessel size and improve identification of vessels suitable for cannulation




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is ≥ 22 years old.
  • Subject is assessed as having fair or poor vein quality.
  • Subject's both arms are suitable for cannulation.
  • Subject will not suffer harm from a delay in having an IV established as determined by the treating clinician.

Exclusion Criteria:

  • Subject has existing intravenous access.
  • Subject has a planned or existing intra-arterial access.
  • Subject has broken, infected or irritated skin and/or dermatological conditions, e.g., eczema, psoriasis and/or allergic reactions, on either forearm.
  • Subject has an active implantable medical device.
  • Subject wears a transdermal drug delivery patch on her/his forearm.
  • Subject has an active/suspected deep vein thrombosis or thrombophlebitis, impaired circulation, impaired sensation, active/uncontrolled bleeding, recently radiated tissue, recent fracture, recent injury or surgery resulting in blood loss > 100 mL, osteoporosis, localized abscess, localized tuberculosis, and/or a chronic wound with potential underlying osteomyelitis.
  • Subject has impaired cognition or communication (unable to provide accurate feedback).
  • Subject has a history of seizures and/or epilepsy, and/or a recent seizure, possible recent seizure or a history of possible seizures.
  • Subject is pregnant and/or breastfeeding at the time of study enrollment.
  • Subject has, at the site of or in between Veinplicity electrode application sites, an active/suspected malignancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03752632


Locations
Layout table for location information
United States, Minnesota
Midwest Immunology Clinic and Infusion Center
Plymouth, Minnesota, United States, 55446
Mayo Clinic-Rochester
Rochester, Minnesota, United States, 55905
Regions Hospital
Saint Paul, Minnesota, United States, 55101
Sponsors and Collaborators
Physeon GmbH
Regulatory Clinical Research Institute (RCRI)
Investigators
Layout table for investigator information
Principal Investigator: Gregory J Schears, MD Mayo Clinic
Layout table for additonal information
Responsible Party: Physeon GmbH
ClinicalTrials.gov Identifier: NCT03752632    
Other Study ID Numbers: PHY0011
First Posted: November 26, 2018    Key Record Dates
Last Update Posted: October 30, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Physeon GmbH:
intravenous
peripheral vein
cannulation
IV access